{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:16:16Z","timestamp":1792444576411,"version":"4.5.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Advanced systemic mastocytosis (AdvSM) is a rare myeloid neoplasm, driven by the KIT D816V mutation in &amp;gt;90% of patients. Avapritinib, a potent, highly selective D816V-mutant KIT inhibitor, is approved for treatment of adults with AdvSM by the US Food and Drug Administration, regardless of prior therapy, and the European Medicines Agency for patients with prior systemic therapy, based on EXPLORER (#NCT02561988; clinicaltrials.gov) and PATHFINDER (#NCT03580655; clinicaltrials.gov) clinical studies. We present latest pooled efficacy and safety analyses from patients who received \u22651 systemic therapy prior to avapritinib in EXPLORER\/PATHFINDER. Overall response rate in response-evaluable patients (n\u00a0= 31) was 71% (95% confidence interval: 52% to 86%; 22\/31), including 19% (6\/31) with complete remission (CR)\/CR with partial recovery of peripheral blood counts (CRh). Median time to response was 2.3 months, median time to CR\/CRh was 7.4 months, and median duration of response (DOR) was not reached. Reductions \u226550% in bone marrow mast cell infiltration (89%), KIT D816V variant allele fraction (66%), serum tryptase (89%), and reductions \u226535% in spleen size (70%) occurred in most patients. Median OS was not reached (median follow-up 17.7 months). Avapritinib was effective in all AdvSM subtypes, regardless of number\/type of prior therapies or poor prognostic somatic mutations. Treatment-related adverse events (TRAEs) were observed in 94% of patients, most commonly grade 1\/2; 57% had TRAEs of at least grade 3; 81% remained on treatment at 6 months. Avapritinib in adults with AdvSM who received prior systemic therapy was generally well tolerated, with high response rates regardless of prior systemic therapy.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007539","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T17:03:37Z","timestamp":1654016617000},"page":"5750-5762","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":45,"title":["Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis"],"prefix":"10.1182","volume":"6","author":[{"given":"Andreas","family":"Reiter","sequence":"first","affiliation":[{"name":"1Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Schwaab","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7865-2306","authenticated-orcid":false,"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Stanford Cancer Institute\/Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2987-1331","authenticated-orcid":false,"given":"Michael W.","family":"Deininger","sequence":"additional","affiliation":[{"name":"4Versiti Blood Research Institute and Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen M.","family":"Pettit","sequence":"additional","affiliation":[{"name":"5Division of Hematology\/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"Alvarez-Twose","sequence":"additional","affiliation":[{"name":"6Institute of Mastocytosis Studies of Castilla-La Mancha (CLMast) and Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer (CIBERONC), Spanish Reference Center of Mastocytosis, Toledo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-0730","authenticated-orcid":false,"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"7Center for Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6316-3112","authenticated-orcid":false,"given":"Jens","family":"Panse","sequence":"additional","affiliation":[{"name":"8Department of Oncology, Hematology, Hemostaseology, and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1863-3239","authenticated-orcid":false,"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[{"name":"9Clinic and Polyclinic for Hematology, Cell Therapy and Hemostaseology, Leipzig University, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Rare Diseases Reference Center for Mastocytoses (CEREMAST), Assistance Publique-H\u00f4pitaux de Paris (APHP)-Necker-Enfants Malades Hospital, and Imagine Institute-INSERM U1163, Paris University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3229-3069","authenticated-orcid":false,"given":"Ingunn","family":"Dybedal","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Min","family":"Lin","sequence":"additional","affiliation":[{"name":"12Blueprint Medicines Corporation, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana N.","family":"Rylova","sequence":"additional","affiliation":[{"name":"13Blueprint Medicines International (Switzerland), Zug, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Ehlert","sequence":"additional","affiliation":[{"name":"14Blueprint Medicines (Germany) GmbH, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u0161a","family":"Dimitrijevi\u0107","sequence":"additional","affiliation":[{"name":"13Blueprint Medicines International (Switzerland), Zug, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti H.","family":"Radia","sequence":"additional","affiliation":[{"name":"15Guy\u2019s & St Thomas\u2019s NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"issue":"1","key":"2023053013342600000_bib1","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.med.55.091902.103822","article-title":"Systemic mastocytosis","volume":"55","author":"Akin","year":"2004","journal-title":"Annu Rev Med"},{"issue":"5","key":"2023053013342600000_bib2","doi-asserted-by":"crossref","first-page":"e2266","DOI":"10.1371\/journal.pone.0002266","article-title":"Case-control cohort study of patients\u2019 perceptions of disability in mastocytosis","volume":"3","author":"Hermine","year":"2008","journal-title":"PLoS One"},{"issue":"23","key":"2023053013342600000_bib3","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2023053013342600000_bib4","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/ajh.26118","article-title":"Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management","volume":"96","author":"Pardanani","year":"2021","journal-title":"Am J Hematol"},{"issue":"11","key":"2023053013342600000_bib5","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2023053013342600000_bib6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"issue":"21","key":"2023053013342600000_bib7","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.18632\/oncotarget.4213","article-title":"Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder","volume":"6","author":"Chatterjee","year":"2015","journal-title":"Oncotarget"},{"issue":"7","key":"2023053013342600000_bib8","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2023053013342600000_bib9","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jmoldx.2010.10.004","article-title":"Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay","volume":"13","author":"Kristensen","year":"2011","journal-title":"J\u00a0Mol Diagn"},{"issue":"1","key":"2023053013342600000_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00277-013-1964-1","article-title":"The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis","volume":"93","author":"Erben","year":"2014","journal-title":"Ann Hematol"},{"issue":"16","key":"2023053013342600000_bib11","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood.2019000932","article-title":"New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis","volume":"135","author":"Reiter","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2023053013342600000_bib12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/joim.12410","article-title":"Mastocytosis: the puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease","volume":"279","author":"G\u00fclen","year":"2016","journal-title":"J\u00a0Intern Med"},{"key":"2023053013342600000_bib13","first-page":"77","article-title":"Novel approaches to treating advanced systemic mastocytosis","volume":"11","author":"Gilreath","year":"2019","journal-title":"Clin Pharmacol"},{"issue":"26","key":"2023053013342600000_bib14","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2023053013342600000_bib15","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3324\/haematol.2017.163964","article-title":"The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm","volume":"102","author":"Jawhar","year":"2017","journal-title":"Haematologica"},{"issue":"12","key":"2023053013342600000_bib16","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/S2352-3026(19)30166-8","article-title":"International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study","volume":"6","author":"Sperr","year":"2019","journal-title":"Lancet Haematol"},{"issue":"2","key":"2023053013342600000_bib17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2017-01-764423","article-title":"Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers","volume":"130","author":"Jawhar","year":"2017","journal-title":"Blood"},{"issue":"16","key":"2023053013342600000_bib18","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1200\/JCO.21.01849","article-title":"Superior efficacy of midostaurin over cladribine in advanced systemic mastocytosis: a registry-based analysis","volume":"40","author":"L\u00fcbke","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2023053013342600000_bib19","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3324\/haematol.2010.031690","article-title":"Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis","volume":"96","author":"Wilson","year":"2011","journal-title":"Haematologica"},{"issue":"24","key":"2023053013342600000_bib20","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1182\/blood-2011-12-397588","article-title":"In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells","volume":"120","author":"Soucie","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2023053013342600000_bib21","doi-asserted-by":"crossref","first-page":"e43090","DOI":"10.1371\/journal.pone.0043090","article-title":"Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis","volume":"7","author":"Traina","year":"2012","journal-title":"PLoS One"},{"issue":"14","key":"2023053013342600000_bib22","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2023053013342600000_bib23","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1182\/bloodadvances.2018020628","article-title":"Impact of somatic and germline mutations on the outcome of systemic mastocytosis","volume":"2","author":"Mu\u00f1oz-Gonz\u00e1lez","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"2023053013342600000_bib24","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"issue":"31","key":"2023053013342600000_bib25","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1200\/JCO.19.00640","article-title":"MARS: Mutation-Adjusted Risk Score for advanced systemic mastocytosis","volume":"37","author":"Jawhar","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"2023053013342600000_bib26","unstructured":"Novartis Europharm Limited\n          . Summary of Product Characteristics. Accessed 19 October 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rydapt-epar-product-information_en.pdf."},{"key":"2023053013342600000_bib27","unstructured":"Novartis Pharmaceuticals Corporation\n          . Prescribing Information. Accessed 19 October 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/207997s000lbl.pdf."},{"issue":"suppl 1","key":"2023053013342600000_bib28","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1182\/blood-2018-99-116465","article-title":"Treatment of patients with aggressive systemic mastocytosis, mast cell leukemia and mast cell sarcoma: a single center experience","volume":"132","author":"Gleixner","year":"2018","journal-title":"Blood"},{"issue":"10","key":"2023053013342600000_bib29","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3324\/haematol.2016.146563","article-title":"Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice","volume":"101","author":"Ustun","year":"2016","journal-title":"Haematologica"},{"issue":"8","key":"2023053013342600000_bib30","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.bbmt.2016.04.018","article-title":"Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis","volume":"22","author":"Ustun","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"414","key":"2023053013342600000_bib31","doi-asserted-by":"crossref","first-page":"eaao1690","DOI":"10.1126\/scitranslmed.aao1690","article-title":"A\u00a0precision therapy against cancers driven by KIT\/PDGFRA mutations","volume":"9","author":"Evans","year":"2017","journal-title":"Sci Transl Med"},{"key":"2023053013342600000_bib32","author":"DeAngelo","year":"2017"},{"issue":"12","key":"2023053013342600000_bib33","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","volume":"27","author":"DeAngelo","year":"2021","journal-title":"Nat Med"},{"issue":"12","key":"2023053013342600000_bib34","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat Med"},{"key":"2023053013342600000_bib35","unstructured":"Blueprint Medicines Corporation\n          . AYVAKIT Prescribing Information. Accessed 23 June 2022. https:\/\/www.blueprintmedicines.com\/uspi\/AYVAKIT.pdf."},{"key":"2023053013342600000_bib36","unstructured":"BioSpace. Blueprint Medicines' AYVAKYT (avapritinib) Receives European Commission Approval for the Treatment of Adults with Advanced Systemic Mastocytosis. Accessed 23 June 2022. https:\/\/www.biospace.com\/article\/releases\/blueprint-medicines-ayvakyt-avapritinib-receives-european-commission-approval-for-the-treatment-of-adults-with-advanced-systemic-mastocytosis\/#:~:text=All%20(725%2C521)-,Blueprint%20Medicines'%20AYVAKYT%C2%AE%20(avapritinib)%20Receives%20European%20Commission%20Approval,Adults%20with%20Advanced%20Systemic%20Mastocytosis."},{"issue":"13","key":"2023053013342600000_bib37","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2012-09-458521","article-title":"International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis","volume":"121","author":"Gotlib","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2023053013342600000_bib38","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/21\/5750\/2054173\/blooda_adv-2022-007539-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/21\/5750\/2054173\/blooda_adv-2022-007539-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T09:36:38Z","timestamp":1685439398000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/21\/5750\/485432\/Efficacy-and-safety-of-avapritinib-in-previously"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":38,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2022,11,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007539","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,8]]}}}